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The interactions of transformed cells with the surrounding stromal cells are of importance for tumor progres-
sion and metastasis. The relevance of adipocyte-derived factors to breast cancer cell survival and growth is well 
established. However, it remains unknown which specific adipocyte-derived factors are most critical in this 
process. Collagen VI is abundantly expressed in adipocytes. Collagen–/– mice in the background of the mouse 
mammary tumor virus/polyoma virus middle T oncogene (MMTV-PyMT) mammary cancer model demonstrate 
dramatically reduced rates of early hyperplasia and primary tumor growth. Collagen VI promotes its growth-
stimulatory and pro-survival effects in part by signaling through the NG2/chondroitin sulfate proteoglycan 
receptor expressed on the surface of malignant ductal epithelial cells to sequentially activate Akt and β-catenin 
and stabilize cyclin D1. Levels of the carboxyterminal domain of collagen VIα3, a proteolytic product of the full-
length molecule, are dramatically upregulated in murine and human breast cancer lesions. The same fragment 
exerts potent growth-stimulatory effects on MCF-7 cells in vitro. Therefore, adipocytes play a vital role in defin-
ing the ECM environment for normal and tumor-derived ductal epithelial cells and contribute significantly to 
tumor growth at early stages through secretion and processing of collagen VI.
Introduction
The interactions between malignant ductal epithelial cells and the 
surrounding stromal cells play a critical role in mammary tumor 
progression (1–3). Myofibroblasts, macrophages, fibroblasts, and 
adipocytes have been demonstrated to interact with breast can-
cer cells (4, 5). The adipocyte is one of the predominant stromal 
cell types in the microenvironment of mammary tissue as well 
as in bone marrow, an area frequently fostering metastases dur-
ing breast cancer progression. A supportive role of adipocytes for 
tumor growth has previously been demonstrated by coinjection 
of tumor cells with adipocytes (6), and many more studies have 
elaborated on the vital role of tumor-stromal interactions for the 
development and progression of cancer (7, 8).
The adipocyte is a potent source of signaling molecules, several 
of which are uniquely produced in this cell type (reviewed in ref. 
9). We have previously shown that type VI collagen is upregulated 
during murine mammary tumor progression (4). Type VI collagen, 
while expressed by a number of other cell types, is abundantly pro-
duced and secreted by adipocytes. Our earlier studies have shown 
that adipose tissue represents the single most abundant source of 
collagen VI systemically (10). Collagen VI is composed of 3 chains, 
α1, α2, and α3, which associate to form higher-order complexes 
(11). The 3 chains of collagen VI form intracellular heterotrimers 
that subsequently form higher-order complexes of tetramers of 
trimers before being secreted. Collagen VI contributes essential 
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functions to the local ECM environment by providing structural 
support for cells and enrichment of growth factors, cytokines, and 
other ligands on cell surfaces and, in fact, can itself assume impor-
tant signaling effects (12).
Increased stromal expression of collagen VI has been correlated 
with various aspects of tumorigenesis and malignant progres-
sion. Specifically, the α3 subunit of collagen VI is upregulated 
in the stroma surrounding colonic tumors compared with that 
surrounding normal tissue (13). Exposure of fibroblasts to colla-
gen VI promotes proliferation and upregulation of cyclin D1 (14). 
Collagen VI can also increase cell migration and invasion in cells 
expressing the NG2/chondroitin sulfate proteoglycan 1 (NG2/
CSPG) receptor (15). Furthermore, the protein inhibits apoptosis 
in a variety of cell types (16). TGF-β–expressing melanoma cells 
induce collagen VI expression in mammary stroma, facilitating 
tumor progression and invasiveness (17). Most recently, increased 
collagen VI expression in the ECM has been associated with the 
promotion of chemoresistance in ovarian cancer cells (18).
Here, we explored the bi-directional interactions between 
adipocytes and malignant ductal epithelial cells via the ECM. 
Using mice lacking the gene encoding the α1 chain of collagen 
VI, which effectively gives rise to a functional null phenotype for 
holo-collagen VI (19), we demonstrate that collagen VI promotes 
the development of hyperplastic foci and primary tumor growth, 
as judged by a markedly reduced rate of early hyperplasia and pri-
mary tumor growth in the collagen VI–/– mice in the background of 
a breast cancer–prone mouse strain (MMTV-PyMT) (20). Collagen 
VI activates the pro-survival and proliferation pathways involving 
Akt, β-catenin, and cyclin D1 to achieve this effect. Use of laser-cap-
ture microdissection and reverse-phase protein arrays verifies this 
mechanism in vivo and illustrates the important role of adipocyte-
derived collagen VI in the process. Immunohistochemistry, protein 
arrays, in vivo imaging, and signaling studies with recombinant 
protein argue for an important role for a collagen VIα3 carboxy-
terminal proteolytic fragment during early tumor development. 
Transplantation studies verify the important role of adipocytes 
and collagen VI in regulation of early tumor development. Com-
bined, our observations provide critical evidence for the important 
involvement of adipocyte-derived factors at early, but not at late, 
stages of mammary tumor progression and offer unique signaling 
mechanisms to account for these effects.
Results
The absence of collagen VI delays the onset of early hyperplasia. Northern 
blot analysis has previously shown that expression of collagen VI is 
highly enriched in adipose tissue and strongly induced during dif-
ferentiation (10). Immunohistochemistry and immunofluorescence 
showed a strong positive signal for collagen VI protein on the sur-
face of murine mammary adipocytes. Given the upregulation of 
collagen VI during tumor progression (4), we wanted to determine 
whether this upregulation is a secondary result of tumor growth 
or whether it has direct functional importance for tumor progres-
sion. To test a possible in vivo role of collagen VI, we opted to take 
advantage of MMTV-PyMT transgenic mice. In addressing the rel-
evance of collagen VI, we crossed MMTV-PyMT mice with collagen 
VI–/– mice (19). Collagen VI–/– mice carry a genetic deletion in the 
α1 locus, resulting in failure to secrete the α2 and α3 subunits, and 
are functional knockouts for the entire collagen VI molecule. The 
initial characterization of these collagen VIα1–/– animals revealed 
no striking phenotypic changes except mild histological signs of 
myopathy in skeletal muscle of both homo- and heterozygous 
mutant animals (19). This myopathy resembled pathologically 
Bethlem myopathy, a human inherited syndrome correlated with 
collagen VI genes (21–23). Subsequent characterization has revealed 
mitochondrial dysfunction and increased levels of apoptosis in 
myocytes of these mice (24).
The mammary epithelium of PyMT transgenic mice in the WT 
background versus the collagen VI–/– background was compared 
at 3–4 and 5–6 weeks. Whole mounts were generated from 1 set 
of inguinal mammary glands (the fourth), and H&E staining was 
performed on the corresponding contralateral glands. Early dys-
plastic foci representing mammary hyperplasia could be seen as 
early as 3–4 weeks in the PyMT+ColVI+/+ mice (Figure 1A). These 
foci occupied approximately 5 times the area of the dysplastic foci 
in the PyMT+ColVI–/– mice. The PyMT+ColVI+/– mice exhibited lev-
els of early hyperplasia closer to those of the PyMT+ColVI+/+ mice 
than to those of the PyMT+ColVI–/– mice. The differential levels of 
early hyperplasia were maintained through the 5- to 6-week time 
period, when a similar 4- to 5-fold difference in area occupied by 
early dysplastic foci or mammary intraepithelial neoplasias (MINs) 
was observable (Figure 1B). Importantly, there was less than a 
10% difference in the number of foci counted at weeks 3 and 6 in 
PyMT+ColVI+/+ mice compared with PyMT+ColVI–/– mice (Figure 
1C). Hence, the actual number of transformed cells leading to foci 
was comparable, excluding nonspecific effects on the PyMT anti-
gen in a collagen VI–/– background. There was, however, a dramatic 
difference with respect to the ability of the foci to proliferate and 
progress through development in the collagen VI–/– background.
The whole mounts and H&E-stained slides were subsequently 
examined according to the recommendations from the Annapolis 
meeting (25). At approximately 4 weeks, mammary glands from 
the knockout mice showed few small MINs involving the ducts 
and the terminal duct lobular units (TDLUs) (Figure 1D). These 
lesions were low grade and characterized by layers of atypical hyper-
chromatic epithelial cells with little cytoplasm. Some of the ducts 
showed surrounding fibrosis and inflammatory cells both in the 
wall and surrounding the involved ducts. The lesions seen in the 
PyMT+ColVI–/– mice were also present in the PyMT+ColVI+/+ and 
PyMT+ColVI+/– mice, though the lesions were more extensive in 
the latter 2, in that they involved more ducts and TDLUs. In some 
of the more extensive lesions, MIN-involved ducts were filled with 
cells such that no lumen was apparent. The cells were of medium-
grade atypia with 4–7 mitotic figures per high-powered field. These 
lesions were multifocal. Histologically, the MIN lesions were seen 
as simple (semicystic bulges along the ducts containing 1 to sev-
eral layers of atypical cells), solid (larger lesions containing dense 
masses of atypical cells in sheets), cystic (containing central fluid-
filled spaces, lined by multilayered epithelium that was frequently 
papillary), and mixed solid and cystic.
Collagen VI promotes primary tumor growth in vivo. The effects 
observed at early stages of tumor development are rather dra-
matic. To determine the long-term consequences of the lack of 
collagen VI for tumor growth, another cohort of PyMT+ColVI+/+, 
PyMT+ColVI+/–, and PyMT+ColVI–/– mice was generated, and pri-
mary tumor formation was monitored over 10 months. Both 
male and female PyMT+ColVI+/+ mice exhibited quicker and 
more widespread induction of primary tumor development than 
PyMT+ColVI–/– mice. In both males and females, PyMT+ColVI+/– 
mice displayed an intermediate phenotype, suggesting a dose-
dependent effect of collagen VI on tumor growth. PyMT+ColVI+/+ 
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mice had palpable tumors as early as 1 month, while PyMT+ColVI–/– 
mice did not produce palpable tumors until 3 months. This differ-
ence in tumor size remained evident throughout the bulk of the 
observation period (10 months) (Figure 1E). The PyMT+ColVI+/+ 
mice exhibited tumors that were 4- to 6-fold larger, based on the 3 
largest tumors in a given mouse, than those found in PyMT+ColVI–/– 
mice. For instance, at month 5, tumors in the collagen VI+/+ females 
were 2,488 ± 237 mm3 on average, whereas those in the knockout 
background averaged 445 ± 27 mm3. Tumors in the heterozygote 
collagen VI background were between the 2 averages but closer 
to WT levels (Figure 1E, left graph). Only by the latest stages (10 
months), the tumors in the female PyMT+ColVI–/– mice caught up 
in size and number with those in the PyMT+ColVI+/+ mice. Results 
from the male transgenics displayed similar differences in pat-
terns of tumor development (Figure 1E, right graph). Important-
ly, PyMT+ColVI+/+ and PyMT+ColVI–/– mice were injected with an 
equal number (105) of metastatic tumor cells (Met1 cells) derived 
from an isogenic PyMT+ mouse. The number of lung metastases 
was determined at several time points after injection. No difference 
in the number of lung metastases was observed at any stage (see 
Supplemental Figure 1; supplemental material available online 
with this article; doi:10.1172/JCI200523424DS1). Therefore, the 
homing and growth of metastatic lesions are unaffected by the 
absence of collagen VI.
As an additional control, we examined murine mammary ductal 
architecture to determine whether the absence of collagen VI influ-
ences normal ductal development of the mammary tree. To assess 
this possibility, we examined whole mounts of knockout mam-
mary glands at various stages of development. No striking differ-
ences can be observed between WT and null mice. This is further 
corroborated by a quantitative analysis, since there was statistically 
no significant difference in the amount of terminal branching in 
comparable regions of the mammary glands (data not shown). In 
addition, there were no functional differences in mammary tissue 
Figure 1
Lack of collagen VI leads to a reduction in tumor growth. (A) Whole-mount analysis of early hyperplasia in 6-week-old collagen VI+/+ or collagen 
VI–/– MMTV-PyMT transgenic mice. Bottom panel: whole mount from a WT mouse. (B) Collagen VI reduction in hyperplastic foci size. Quantitation 
of hyperplastic areas at 3 and 6 weeks. n = 5 mice per group. *P < 0.05 vs. WT. (C) Number of hyperplastic foci does not significantly depend on 
collagen VI presence or absence in the MMTV-PyMT mouse. Quantitation of the number of foci formed in the mammary glands of 3-week-old 
MMTV-PyMT mice. n = 5 mice per group. (D) A representative H&E stain of a mammary section taken from PyMT+ColVI–/– and PyMT+ColVI+/+ 
mice at 6 weeks of age. (E) Quantitation of tumor sizes of female and male PyMT+ mice at different ages. n = 10 for each group. The 3 largest 
lesions were measured in each mouse. (F) Adipocytes (adip), but not breast cancer cells, express collagen VI, whereas breast cancer cells, but 
not adipocytes, express the collagen VI receptor NG2/CSPG. RT-PCR was performed to determine expression levels of NG2 and collagen VI. 
Lane 1, human adipocytes; lane 2, Marker (Mr; DNA ladder); lanes 3 and 4, MCF-7 cells; lanes 5 and 6, MCF-7 cells with adipocyte-conditioned 
medium; lanes 7 and 8, 3T3-L1 adipocytes; lane 9, MCF-7 cells; lane 10, MCF-7 cells with adipocyte-conditioned medium. (G) Expression of col-
lagen VI in mammary adipocytes and early- and late-stage tumors. Quantitative real-time PCR was conducted. GAPDH was used as an internal 
control. Values for early-stage tumor samples were arbitrarily set to 1.
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between the genotypes, since collagen VI–/– mice are fully fertile, 
have normal litter sizes, lactate, and have pup survival rates com-
parable to those of WT.
Another important analysis involved identifying the local sources 
and relative contributions of collagen VI in mammary microenvi-
ronments. Our previous paper had suggested that adipocytes were 
the primary local producers of collagen VI as determined by in situ 
hybridization (4). To further illustrate the prime importance of 
adipocyte-specific collagen VI expression within mammary glands, 
we conducted several experiments. RT-PCR of human adipocytes 
and cultured MCF-7 cells suggested that the adipocytes expressed 
collagen VI but not the cell surface receptor NG2/CSPG whereas 
the MCF-7 cells expressed the latter gene but were not express-
ing measurable quantities of collagen VI message (Figure 1F). To 
take this experiment one step further, we took murine adipose tis-
sue and sections of early- and late-stage tumors and performed 
quantitative real-time PCR for collagen VI expression. Adipocytes 
were specifically isolated from the mammary adipose tissue using 
collagenase I treatment of the specimen. Multiple early- and late-
stage tumor tissues from 3 mice each were taken, pooled, and 
snap-frozen. RNA isolation, reverse transcription, and quantita-
tive real-time PCR were performed. The data highlighted the dif-
ferential levels of collagen VIα3 message in the local mammary 
microenvironments, illustrating that adipocytes represented the 
major source of collagen VI at all stages of tumor growth (Figure 
1G). As the tumors became larger, they expressed 4 times as much 
collagen VI as early tumors but still significantly lagged behind the 
adipocytes normalized for β-actin message.
Collagen VI–secreting adipocytes are more permissive of breast tumor 
growth in vivo and have a greater impact on the progression of early 
tumor development. Given the dramatic reduction of tumor growth 
in collagen VI–/– mice in the background of an MMTV-PyMT 
transgene, we wanted to assay the ability of collagen VI secreted 
from adipocytes to support mammary tumor growth indepen-
dently. Athymic nude mice were injected with estrogen receptor–
negative SUM-159PT breast cancer cells (26) mixed with purified 
adipocytes isolated from collagen VI+/+, collagen VI+/–, and collagen 
VI–/– mice or 3T3-L1 adipocytes. For these experiments, primary 
adipocytes were prepared by collagenase digestion, and all other 
stromal cell types were removed by centrifugation. This procedure 
yielded a highly purified preparation of adipocytes. There was no 
difference in the level of structural integrity between WT and null 
adipocytes. Upon coinjection, tumors were allowed to grow for a 
period of 4 weeks. At the end of the experiment, tumor size was 
measured, and the tumor mass was excised and stained for the 
presence of the human ErbB2 antigen to confirm the presence 
of the human SUM-159PT cells. Primary collagen VI+/+-derived 
adipocytes and 3T3-L1 adipocytes best supported tumor growth 
and promoted the development of foci up to 300 mm3 and 500 
mm3, respectively (Figure 2A). Adipocytes from either collagen 
VI+/– mice or collagen VI–/– mice supported foci only up to 100 
mm3. In line with our previously published results (4), 3T3-L1 
adipocytes promoted SUM-159PT foci formation in vivo very 
well. Asterisks highlight the results that were statistically signifi-
cant and differed from the growth of tumor foci provided WT, 
collagen VI–expressing adipocytes (Figure 2A). Similar studies 
were performed with estrogen receptor–positive MCF-7 cells, cor-
roborating the data obtained with the estrogen receptor–negative 
SUM cells. Adipocytes derived from WT mice and the 3T3-L1 cell 
line accommodated development of MCF-7 foci to an average 
size of approximately 289 mm3 and 533 mm3, respectively. The 
adipocytes taken from mice heterozygous and null for collagen VI 
had reduced capacity to promote MCF-7 growth, with foci reach-
ing an average volume of 115 mm3.
An additional study was performed to assess the capacity of 
collagen VI–secreting cells in influencing early versus late tumor 
progression. These experiments suggested that the lack of adipose 
tissue (and collagen VI) has no impact on the tumor progression 
(size) and metastatic potential of late-stage malignant lesions 
(Supplemental Figure 2). Figure 1 pointed to the role of collagen VI 
in early neoplastic processes. With the experiment described below, 
we were able to specifically study the effect of collagen VI on early- 
and late-stage tumor progression. Small sections of tumors were 
isolated from early- and late-stage lesions in PyMT+ColVI+/+ mice 
as outlined in Methods. The tumor pieces of equal size were then 
transplanted into the partially cleared fat pads of collagen VI+/+ 
and collagen VI–/– mice. After 3 weeks the mice were sacrificed and 
the transplanted lesions examined with whole-mount and H&E 
Figure 2
Adipocytes from collagen VI+/– and collagen VI–/– mice are less potent 
stimulators of tumor growth. Collagen VI also has greater impact on 
early than on late tumor progression. (A) SUM159-PT cells (1 × 105) 
were coinjected into 8-week-old nude mice with the same number of 
isolated primary mammary adipocytes from collagen VI+/+, collagen 
VI+/–, collagen VI–/– mice, or 3T3-L1 adipocytes. Four weeks after injec-
tion, the sizes of the resulting foci were measured. n = 4 mice in each 
cohort. Results are shown as mean ± SEM. (B) MMTV-PyMT trans-
genic mice were sacrificed, and large, late tumor sections (from lesions 
larger than 1,500 mm3) and some small transformed mammary tissue 
for early tumor samples (lesions smaller than 300 mm3) were isolated. 
Tumor pieces were transplanted into partially cleared mammary glands 
of collagen VI+/+ and collagen VI–/– mice (n = 4). After 3 weeks, whole 
mounts were made. The tumor focus had a dense cellular make-up 
in the WT background, compared with reduced cellular density in the 
collagen VI–null host. Tumor areas were quantitated. Note that the 
absence of collagen VI protein does not affect the growth of late-stage 
tumor transplants. *P < 0.05. (C) Collagen VI induces proteins whose 
gene products are upregulated on the DNA microarrays. MCF-7 cells 
were treated for 6 hours with collagen VI or collagen I (each at 30 μg/
ml) and extracts were generated for Western blots. EGR2, ATF4, IL-8, 
and GDI-3 as a loading control were measured. The levels of induction 
seen were similar to those seen by DNA microarrays.
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analysis (Figure 2B). These studies indicated that early tumor cells 
display significantly enhanced growth in a WT host compared 
with a host lacking collagen VI. Collagen VI has, however, less of 
an impact on the tumor growth rate upon transplantation of late 
tumor cells. Combined, these results underlined the importance of 
adipocyte-derived collagen VI for early tumor growth.
Collagen VI induces genes associated with breast cancer progression. In 
order to obtain a global perspective of transcriptional changes 
induced by type VI collagen in mammary ductal epithelial cells, 
DNA microarray experiments were performed. To identify changes 
specifically brought about by collagen VI, we compared the col-
lagen VI–induced transcriptional profile of MCF-7 cells with that 
of cells treated with collagen I. Collagen I treatment served in this 
case as a suitable base line, as it represents another abundant colla-
gen that the epithelial cells are exposed to, prepared under compa-
rable conditions. The cells were treated for 6 hours, and total RNA 
was isolated, reverse transcribed, and used to probe a microarray 
of approximately 9,500 human genes. Collagen VI induced the 
upregulation of a host of genes that either promote tumor devel-
opment or have been positively correlated with breast cancer in 
some other context. These genes 
included human transcription 
factor ETR101, growth factor PC4 
homolog, protein tyrosine kinase 
tyk2, CDC28 protein kinase 1, 
and human metallothionein-1f 
and -1e (Supplemental Table 1). 
Notably, CDC28 protein kinase 1 
promotes cellular proliferation 
via p27 Kip1 degradation, and 
metallothionein-1f/1e is corre-
lated with poor patient prognosis 
in breast cancer. In line with the 
mRNA data, collagen VI mediated 
the upregulation of metallothio-
nein also at the protein level as 
judged by immunohistochemistry 
in metastatic breast cancer cells 
treated with exogenous collagen 
VI protein (data not shown). Since 
metallothioneins are critically 
involved in cisplatin resistance, the 
observed upregulation of metallo-
thionein by collagen VI provided, 
for the first time to our knowledge, 
a mechanistic explanation of why 
cultivation of cisplatin-sensitive 
cells in the presence of collagen VI 
protein promotes cisplatin resis-
tance (18). In addition, collagen VI 
also specifically upregulated ATF3 
and ATF4, transcription factors 
that are positive modulators of 
tumor development and invasion. 
Several other genes that promote 
angiogenesis, tumor growth, and/
or tumor invasion were also found 
to be upregulated (Supplemental 
Table 1). These genes included 
VEGF, calpain 4, IL-8, and angio-
poietin-2. Figure 2C provides representative data for a subset of 
proteins, confirming by Western blot analysis that the observed 
changes at the mRNA level translated effectively into changes at 
the protein level. Proteins tested include EGR2, ATF4, and IL-8. 
Compared with collagen I, collagen VI treatment led to a much 
greater induction of these proteins, at a magnitude similar to that 
of the transcriptional induction seen in the DNA microarrays.
Collagen VI activates Tcf/Lef signaling downstream of glycogen synthase 
kinase-3β phosphorylation. Given the strong evidence for a direct 
involvement of collagen VI in early tumor growth, we wanted to 
gain a better understanding of the underlying molecular mech-
anism that leads to such a strong pro-proliferative and pro-sur-
vival/anti-apoptotic response in breast cancer cells. The Akt-gly-
cogen synthase kinase-3β–β-catenin–Tcf/Lef pathway is relevant 
to tumorigenesis, both in colonic adenocarcinomas and in breast 
tumors (27). The activation of Tcf/Lef, the downstream effector 
in this signaling cascade, induces the transcription of various pro-
oncogenes, including cyclin D1, NF-κB, cFOS, and ATF3 (28). 
Events that lead to the accumulation of β-catenin in the cytoplasm 
increase Tcf/Lef activity. We had previously demonstrated that 
Figure 3
Collagen VI stabilizes β-catenin and cyclin D1. (A) Dose response to increasing concentrations of col-
lagen VI protein. A Tcf/Lef luciferase reporter construct was transfected into MCF-7 cells. Collagen VI 
treatment was for 3 hours. (B) Collagen VI–mediated Tcf/Lef induction. Luciferase activity was analyzed 
after treatment with vehicle, collagen VI (30 μg/ml), or collagen I (30 μg/ml) for 3 hours. (C) Time course 
of induction of Tcf/Lef activity. Luciferase activity was analyzed at different time points after treatment 
with 30 μg/ml collagen VI. (D) β-Catenin stability after collagen exposure. MCF-7 cells were metaboli-
cally labeled and then chased in the presence of cycloheximide for 30 minutes, 1 hour, and 2 hours. The 
chase medium contained vehicle, collagen VI (30 μg/ml), or collagen I (30 μg/ml). β-Catenin and GDI-3 
were immunoprecipitated and quantitated. The ratio of β-catenin at 2 hours compared to 30 minutes was 
plotted as an indicator of β-catenin stability (3 independent experiments). No txt, no treatment. (E) Cyclin 
D1 stability after collagen exposure. MCF-7 cells were exposed for 3 hours to vehicle, human collagen 
VI (30 μg/ml), or collagen I (30 μg/ml). Cells were then lysed and analyzed for cyclin D1 by Western blot 
analysis. (F) Collagen VI acts in part through NG2 in MCF-7 cells to stabilize cyclin D1. In the presence 
of increasing amounts of NG2 neutralizing antibody in the medium (+, 0.15 μg/ml; ++, 0.45 μg/ml; +++, 
0.75 μg/ml; ++++, 1 μg/ml), cyclin D1 levels decrease in a dose-dependent manner. Results are shown 
as mean ± SEM. *P < 0.05.
research article
1168 The Journal of Clinical Investigation   http://www.jci.org   Volume 115   Number 5   May 2005
collagen VI caused phosphorylation of GSK3β (4). Protein kinase 
A and Akt are known upstream kinases that target GSK3β for 
phosphorylation. The TOPFLASH reporter luciferase assay system 
was used here to determine whether collagen VI–induced GSK3β 
phosphorylation led to downstream Tcf/Lef transcriptional acti-
vation in MCF-7 cells. Initial experiments revealed that collagen 
VI works to maximally induce Tcf/Lef luciferase activity to levels 
6- to 8-fold above base line at approximately 3 hours in a time- and 
dose-dependent fashion (Figure 3, A and C). This was a specific 
effect, since exposure to collagen VI, but not to collagen I, caused 
a 6- to 8-fold induction of Tcf/Lef activity (Figure 3B). To corrobo-
rate this and subsequent data in another cell line, SUM cells were 
used. The capacity of collagen VI to signal for increased Tcf/Lef 
activity and β-catenin and cyclin D1 stabilization was preserved in 
the latter cell type as well.
Collagen VI prevents degradation of endogenous β-catenin. Increased cel-
lular β-catenin levels were a likely result of the observed increase in 
GSK3β phosphorylation and Tcf/Lef activity in mammary cancer 
cells induced by collagen VI. To 
test this, β-catenin levels were 
monitored over the course of sev-
eral hours after a pulse-chase reac-
tion. Degradation of 35S-labeled 
β -catenin was evident in 
untreated cells, with decreased 
intracellular levels apparent as 
early as 0.5 to 1 hour followed 
by a further progressive decrease 
apparent by 2 hours. The pres-
ence of collagen VI dramatically 
reduced the rate of degrada-
tion and maintained levels of 
β-catenin over the course of the 
experiment (Figure 3D). In con-
trast, the signal for GDP dis-
sociation inhibitor 3 (GDI-3) is 
relatively long-lived and, con-
sistent with our previously pub-
lished observations, does not 
significantly turn over within a 
2-hour chase period (29). Data 
from several independent experi-
ments were analyzed and quanti-
tated. A marginal stabilization of 
β-catenin was also evident at 
early time points upon treatment 
with collagen I, but increased 
degradation compared with col-
lagen VI–stabilized β-catenin 
was evident after 2 hours. Col-
lagen VI therefore specifically 
enhanced intracellular β-catenin 
activity by decreasing its rate of 
degradation.
Collagen VI increases cyclin D1 
protein stability through NG2/
CSPG. Since cyclin D1 is a known 
target of Tcf/Lef and is affected 
by GSK3β and β-catenin activ-
ity, we tested whether collagen 
VI could regulate cyclin D1 levels in breast cancer cells. MCF-7 
cells were treated with vehicle, collagen VI, or collagen I for 3 
hours, and protein extracts were generated. Collagen VI indeed 
maintained and substantially increased cyclin D1 levels, whereas 
collagen I showed no significant change compared with the vehi-
cle condition (Figure 3E). A possible candidate to mediate these 
effects is the collagen VI receptor NG2/CSPG, a molecule that has 
previously been implicated as a growth mediator in a number of 
cancers (reviewed in ref. 30). The role of NG2/CSPG in the context 
of breast cancer has not, however, been examined. A previously 
described neutralizing antibody preparation against NG2/CSPG 
was used to determine whether the collagen VI effects on cyclin 
D1 expression are indeed exerted through this receptor (31–37). 
MCF-7 cells pretreated with the anti-NG2/CSPG antibody were 
exposed to collagen VI protein, and cyclin D1 levels were moni-
tored. Increasing concentrations of the anti-NG2/CSPG antibody 
in the presence of collagen VI led to progressively lower levels of 
intracellular cyclin D1 (Figure 3F). Antibody treatment in the 
Figure 4
Immunohistochemical analysis of pathologically matched tumors from collagen+/+ and collagen–/– mice in 
the MMTV-PyMT background. (A) Absence of collagen VIα3 signal in collagen–/– mice. Staining for col-
lagen VIα3 (with carboxyterminal polyclonal antibody) on mammary sections from pathologically matched 
hyperplasias developed in collagen+/+ and collagen–/– mice. Arrows point in the direction of increased 
levels of staining. Asterisks denote local mammary adipocytes. Magnification, ×25. (B) NG2/CSPG is 
expressed at the highest levels in malignant regions adjacent to adipocytes in WT mice. Note the positive 
staining in WT backgrounds on the leading edges of the tumor mass. Magnification, ×25. (C) Cyclin D1 
is expressed at the highest levels in malignant regions adjacent to adipocytes. Magnification, ×10. (D) 
GSK3β is phosphorylated at the highest levels in malignant regions adjacent to adipocytes. Magnification, 
×10. (E) Ki67 expression is present in cells proliferating throughout the mammary lesions. Staining for the 
proliferation marker Ki67 in pathologically matched lesions from WT and collagen VI–null mice demon-
strates diffuse expression throughout the tumor masses in both genotypes. Magnification, ×25. (F) Akt is 
phosphorylated and activated at higher levels in tumors that have developed in the presence of collagen 
VI signaling. Staining for the ser473-phosphorylated Akt in pathologically matched tumors from collagen 
VI WT and knockout mice demonstrated significant staining in cells on the tumor periphery in the WT mice 
but not in collagen VI–null mice. Asterisks denote local mammary adipocytes in close proximity to the 
malignancies. Arrowheads point to the pAkt-positive cells. Magnification, ×25.
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absence of added collagen VI had no effect on cyclin D1 stabil-
ity. Pretreatment with a nonspecific control antibody preparation 
before collagen VI exposure did not impair the collagen VI–medi-
ated stabilization of cyclin D1. This suggested that collagen VI 
mediates its effects on intracellular cyclin D1 levels at least in part 
through binding to and activation of the cell surface receptor 
NG2/CSPG. Equal protein loading for all the Western blots and 
labeling experiments was verified by probing for GDI-3.
Immunohistochemical evidence for effects of adipocyte-enriched collagen 
VI on GSK3β and cyclin D1. To lend further support to our in vitro 
observations, we examined sections of hyperplasia and early pri-
mary lesions by immunohistochemistry. Staining for the carboxy 
terminus of collagen VIα3 in PyMT+ColVI+/+ mice was localized 
mainly to the periphery of the tumor masses, appearing in a ring 
pattern around the region of early hyperplasia and around 
the periphery of adipocytes (Figure 4A). A gradient in colla-
gen signal was observed with increased staining of MIN cell 
peripheries closer to adipocytes (Figure 4A; arrows point in 
the direction of increased staining). Staining on the interior 
of regions of early hyperplasia showed weaker collagen VI 
expression. Asterisks denote the local adipocytes in the mam-
mary glands in the various sections. No collagen VI staining 
was observed in PyMT+ColVI–/– mice. Immunohistochemical 
staining for NG2/CSPG demonstrated localization to cell sur-
faces throughout the tumor masses in PyMT+ColVI+/+ mice 
(Figure 4B). The staining was notably more pronounced on 
the surfaces of tumor cells closer to the adipocyte-rich regions. 
In PyMT+ColVI–/– sections that were stained with NG2/CSPG, 
a much lower signal intensity was detected (Figure 4B, bot-
tom panel). When staining for cyclin D1, we observed a ring of 
malignant cells on the outside of the MIN regions that exhib-
ited positive staining in PyMT+ColVI+/+ mice, similar to the 
pattern that was recently reported by Pollard and colleagues 
(38). This ring of cyclin D1 staining was reduced, however, 
in pathologically matched PyMT+ColVI–/– mice (Figure 4C). 
The type of cyclin D1 staining seen in Figure 4 represented 
what would be seen with MINs or at the stage of early tumor 
development (39). The staining pattern for phospho-GSK3β 
(pGSK3β) was similar to that for cyclin D1 (Figure 4D). A gra-
dient was again seen with increased staining intensities closer 
to adipocytes on the leading edges of the hyperplastic lesions. 
Staining was present in matched PyMT+ColVI–/– tumors, 
though the levels were substantially reduced.
To verify that cells in the interiors of the tumor masses were 
still proliferating, immunohistochemistry was performed 
using the polyclonal antibody against the proliferation marker 
Ki67. Early lesions from collagen VI+/+ and collagen VI–/– mice 
were removed, sectioned, and stained for Ki67. As is apparent 
from both panels in Figure 4E, the brown diaminobenzidine 
stain indicative of cells positively expressing Ki67 was present 
throughout the tumor masses in the presence or absence of 
collagen VI. While not all the cells were proliferating, a sig-
nificant proportion of the cells continued to do so both in the 
presence and in the absence of collagen VI.
Along with differences in cyclin D1 and pGSK3β expres-
sion levels in the presence and absence of collagen VI, it is 
also apparent that the phosphorylation of Akt at ser473 
also varied in the tumors derived from the 2 mouse models. 
Based on the increased cyclin D1 and pGSK3β expression in 
mammary tumors from WT mice, it would be expected that 
ser473 phosphorylation of Akt would also be more prevalent 
in the collagen VI+/+ background compared with the null mice. 
Early tumor sections from the 2 mouse lines ColVI+/+MMTV+ and 
ColVI–/–MMTV+ were probed with the anti-pAkt ser473 antibody. 
Figure 4F further underlines that the absence of collagen VI pro-
tein strictly curtailed signaling through the GSK–Akt–cyclin D1 
pathway. The presence of collagen VI allowed for increased pAkt 
expression (arrowheads) in cells on the periphery of the malignan-
cy closest to the interacting adipocytes (asterisks).
Collagen VI activates similar pathways in vivo and in vitro. In light 
of the effects of collagen VI on the generation of dysplastic foci 
and growth of primary tumors, we wanted to better understand 
which signaling pathways critically contribute to this pheno-
type in vivo. Laser-capture microdissection was used to isolate 
Figure 5
Breast tumor cell protein expression and activation differences between col-
lagen VI+/+ and collagen VI–/– mice in the background of the MMTV-PyMT 
transgene. (A) Laser-capture microdissection was used to isolate hyper-
plastic cells in a 100-μM radius from adipocytes. A representative example 
is shown in the top panels, before (panel 1) and after (panel 2) removal of 
cells. Similarly, cells not associated at all with adipocytes (> 500 μM from 
the nearest adipocyte) were isolated from pathologically matched sections 
from mice carrying the MMTV-PyMT transgene in either a collagen VI+/+ or 
a collagen VI–/– background (panels 3 and 4). Arrows indicate the targeted 
areas before and after isolation of cells. (B) Material from at least 8 indepen-
dent areas was pooled in each case and analyzed. The material was used 
to make protein extracts that were spotted on protein arrays. The results 
shown were obtained from arrays of cells in close proximity to adipocytes. 
Arrays were probed with various antibodies against total and activated forms 
of proteins implicated in pro-oncogenic pathways. *P < 0.05. (C) Quantita-
tive comparison of the ratio of phospho-specific protein to total protein from 
arrays used in B. Results are shown as mean ± SEM. *P < 0.05.
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specific cells prior to reverse-phase protein array analysis. Speci-
mens of stage- and size-matched early malignancies isolated from 
PyMT+ColVI+/+, and PyMT+ColVI–/– mice were analyzed. Cells were 
chosen from clusters located at the periphery of the hyperplasias 
in close juxtaposition to adipocytes and from clusters more distal 
to adipocytes (Figure 5A). Proteomic reverse-phase array analy-
sis revealed highly significant differences that demonstrated the 
variable activation states of a number 
of relevant signaling modules in the 
presence and absence of collagen VI 
and adipocytes in general (Figure 5, B 
and C). Most notably, while total Akt 
levels were comparable in cells from 
PyMT+ColVI+/+ and PyMT+ColVI–/– 
mice, a much larger portion of the 
protein was phosphorylated and 
activated in PyMT+ColVI+/+ mice 
(Figure 5C). Similarly, greater per-
centages of GSK3β, IκB, and ErbB2 
were phosphorylated in MIN cells of 
PyMT+ColVI+/+ mice compared with 
pathologically matched hyperplasias 
in PyMT+ColVI–/– mice. While not 
investigated in our in vitro analy-
ses, both STAT1 and NF-κB (p52) 
exhibited increased expression and 
phosphorylation, and STAT1 also 
exhibited increased activation, in 
PyMT+ColVI–/– hyperplastic cells. 
Finally, though there were slightly 
increased levels of the mitogen-acti-
vated protein kinase ERK in hyper-
plasias from knockout animals, there 
were far greater levels of total ERK 
in these same cells. This results in an 
overall lowered activation state of ERK 
in these knockout mice (Figure 5B). 
Perhaps most importantly, the differ-
ences in the activation state of all of 
these signaling components between 
PyMT+ColVI+/+ and PyMT+ColVI–/– 
cells were only observed near the 
periphery of the tumor in proxim-
ity to adipocytes, whereas no signifi-
cant differences in signaling could 
be observed in cells isolated from the 
center (not shown). Several impor-
tant conclusions can be made from 
this study. Firstly, without local 
adipocytes, very few differences could 
be observed in the signaling pathways 
of the neoplastic cells. Secondly, the 
presence or absence of collagen VI had 
a profound influence on signaling and 
posttranslational modifications in the 
malignant breast cancer cells close to 
the adipocytes. Perhaps most signifi-
cantly, these in vivo results corrobo-
rated our previously summarized in 
vitro signaling findings.
Human breast tumor specimens display a collagen VI staining pattern 
similar to that observed in mice. We have previously reported increased 
staining for collagen VI during progression of tumorigenesis in the 
mouse (4). To test whether these observations are relevant to human 
disease, we probed human tumor and normal human mammary 
tissue sections with 2 different antibody preparations: a polyclonal 
antibody raised against the carboxyterminal domain of the collagen 
Figure 6
Increased levels of the C-terminal domain of collagen VIα3 in tumor cells in the proximity of adipo-
cytes. (A) High levels of the carboxyterminal domain of collagen VIα3 in a human mammary tumor 
sample. Top panel: collagen VI staining around human breast carcinoma cells near the vicinity of the 
adipocytes (arrows). Bottom panel: reduced staining in tumor cells more distant from adipocytes in the 
same tumor section. (B) Polyclonal-to-monoclonal ratio of collagen VI. Reverse-phase protein arrays 
determined levels of the C-terminal domain from collagen VIα3 (top) and the full-length collagen VI 
protein (middle) found in normal and tumor tissue of human cancer specimens. Bottom panel: ratio 
of relative signals obtained for polyclonal and monoclonal antibodies, indicating a bias toward higher 
levels of the α3 C-terminal domain. (C) The carboxyterminal fragment of collagen VIα3 accumulates 
on the surface of tumors. Polyclonal IgGs from immune and nonimmune preparations against the 
carboxyterminal domain of collagen VIα3 were radiolabeled with 188-rhenium. Preparations were 
injected either i.p. (top) or i.v. in the tail vein (bottom) into 10-week-old MMTV-PyMT mice. The outline 
of the mouse is indicated. Mice were imaged on a Siemens LEM+ZLC DIGITRAC gamma camera. 
(D) Recombinant carboxyterminal C3–C5 domains of collagen VIα3 display potent pro-mitogenic 
activity. MCF-7 cells were treated with conditioned medium containing recombinant carboxyterminal 
collagen VIα3 protein or conditioned medium from control transfected cells for 24, 48, or 72 hours. 
Cell number was normalized to the control cells at the respective time points. *P < 0.05.
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VIα3 subunit and a commercially available mAb against collagen VI 
that recognizes another, not defined epitope on one of the other 
α chains. Normal mammary glands exhibited relatively low levels 
of collagen VI staining with both antibodies, with a predominant 
signal detectable around adipocytes (data not shown). Late-stage 
carcinomas, however, showed a very intense staining pattern for 
collagen VI around the tumor masses when the antibody directed 
against the carboxyterminal domain of the collagen VIα3 subunit 
was used (Figure 6A). Immunostaining was particularly prominent 
in tumor cells near adipocytes, and less pronounced in cells located 
more distantly from adipocytes. The 2 panels of Figure 6A were 
taken from the same slide and represent human tumor cells clos-
er to (top panel) and further away from (bottom panel) the local 
mammary human adipocytes. Interestingly, in a direct comparison 
of staining patterns, the mAb recognizing the full-length collagen 
complex was associated with diffuse staining around adipocytes, 
whereas the polyclonal antibody against the carboxyterminal 
domain was associated with enhanced staining around tumor cells 
(not shown). This strongly suggested that the α3 carboxyterminal 
domain may have been cleaved from the polymeric remainder of 
the collagen VI. Furthermore, this small soluble domain may in 
turn be the only portion of collagen VI that is directly interacting 
with tumor cells. This points to the α3 carboxyterminal domain as 
a factor that is potentially relevant to cancer progression.
Collagen VI regulation in the human mammary carcinoma. The poten-
tial importance of collagen VI protein may be as an early diagnostic 
marker of mammary hyperplasia or as a growth-promoting factor 
that can be inhibited to reduce tumor progression. To that end, we 
undertook experiments to look at collagen VI protein expression 
in normal and tumor cells from human cancer patients at various 
stages of the disease by using reverse-phase protein microarrays. 
Both the polyclonal antibody against the collagen VIα3 domain 
and the mAb against the collagenous domain of the full-length 
protein were used. Interestingly, the relative levels of the collagen 
VIα3 carboxyterminal domain (Figure 6B, top panel) versus the 
full-length collagen VI protein (Figure 6B, middle panel) were 
strongly biased toward the collagen VIα3 domain in tumor, but 
not in healthy tissue, as judged by the ratio of the signal intensi-
ties obtained with the 2 different antibodies (Figure 6B, bottom 
panel). This suggested that the ratio of the collagen VIα3 carboxy 
terminus to full-length collagen VI may serve as a useful diagnostic 
marker, even in human specimens. Interestingly, this observation 
did not hold up for ErB2-positive tumors.
In vivo imaging of tumors with antibodies recognizing the carboxytermi-
nal domain of collagen VIα3 shows that the recombinant carboxyterminal 
fragment of the collagen VIα3 protein has the functional capacity to signal 
and promote tumor cell proliferation. In order to gain a systemic over-
view of the relative enrichment of the carboxyterminal domain of 
collagen VIα3, we isolated polyclonal IgGs from immune and non-
immune preparations and radiolabeled them with 188-rhenium. 
Preparations were injected either i.p. (Figure 6C, top) or i.v. in the 
tail vein (Figure 6C, bottom) into an established murine breast can-
cer model, a transgenic mouse expressing the polyoma middle T 
antigen under the control of the MMTV promoter (MMTV-PyMT) 
(20). These mice were subsequently imaged on a gamma camera. 
Whereas the preimmune IgGs rapidly accumulated in the kidneys, 
the immune IgGs specifically accumulated on the tumor mass; 
this suggests that the carboxyterminal domain of collagen VIα3 
is highly enriched on the surface of tumors cells and may serve as 
a potent biomarker for breast tumor cells. Finally, to demonstrate 
that this carboxyterminal fragment was not merely a byproduct 
of tumor progression but an active pro-mitogenic player during 
the process, we transiently transfected HEK-293T cells with a 
cDNA construct encoding a signal sequence fused to the C3 to 
C5 domains of collagen VIα3. This protein was efficiently secreted 
from the producer HEK-293T cells (not shown). MCF-7 cells were 
plated in 6-well dishes and exposed to conditioned (serum-free) 
supernatant harvested from cells expressing this C3–C5 collagen 
VIα3 fragment, or to conditioned medium from cells transfected 
with a plasmid lacking this cDNA insert. The fragment exerted 
potent growth-stimulatory properties on MCF-7 cells even in this 
isolated in vitro setting (Figure 6D).
Discussion
The ECM affects breast ductal epithelial cells at multiple levels, 
including by helping to remodel ductal architecture, influencing 
cell morphology, modulating proliferation through direct action 
on ductal epithelial cells, and acting as a reservoir for circulating 
growth factors. Under normal conditions, the basement mem-
brane forms an effective barrier between the ductal epithelium and 
the surrounding stromal cells, but upon neoplastic transforma-
tion, the ductal cells break through the basement membrane and 
are subsequently in direct contact with a new extracellular milieu. 
Adipocytes, the most abundant cell type in the stroma, are highly 
active endocrine cells that not only secrete a host of soluble factors 
but also contribute very significantly to the unique makeup of the 
ECM. Our previous work characterized the effects that the entire 
complement of soluble secretory products from adipocytes exerts 
on survival and growth of ductal epithelial cells (4). Here, we have 
focused on the role of an abundant, adipocyte-enriched ECM com-
ponent, type VI collagen, and, for the first time to our knowledge, 
we implicate collagen VI both genetically and biochemically in the 
pathophysiology of breast cancer.
The upregulation of collagen VI observed during murine tumor 
progression suggested that collagen VI has the potential to influ-
ence breast cancer progression in vivo. Our genetic evidence, 
derived from the analysis of PyMT+ColVI+/+, PyMT+ColVI+/–, and 
PyMT+ColVI–/– mice, strongly supports the involvement of colla-
gen VI in the early developmental progression of dysplastic foci 
and the promotion of primary tumor growth. The absence of col-
lagen VI did not have an effect on the number of dysplastic foci 
observed as measured by MINs and TDLUs. No other systemic 
effects were observed. We have demonstrated here that the effi-
ciency of early hyperplastic and primary tumor growth was dra-
matically reduced in the absence of collagen VI.
In murine mammary glands, the adipocytes are immediately 
adjacent to the ductal epithelial cells, whereas in human mam-
mary glands, a fibrous layer separates the 2 cell types; this sug-
gests that the observations made in murine models may have to be 
interpreted with caution. However, the adipocyte is clearly secret-
ing soluble matrix proteins, cytokines, growth factors, and other 
molecules that can diffuse to the tumor cells and interact with 
ductal epithelial cell receptors in human samples. By depositing 
these factors into the fibrous layer, adipocytes can add to the types 
of signals reaching the cancer cells. Secondly, the malignant duc-
tal epithelial cells can locally invade this fibrous layer in human 
mammary glands, thereby getting in direct cell-cell contact with 
the fatty tissue. Finally, some types of breast cancers, including 
the lobular type, have much more interaction with fat tissue than 
other types very early in tumor development.
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Reconstitution studies were used to further examine whether 
collagen VI is a necessary driving force for tumor progression. 
3T3-L1 adipocytes (an established adipocyte cell line) and isolated 
primary adipocytes that secrete collagen VI both supported for-
mation and growth of tumor foci in coinjection experiments with 
SUM-159PT cells. Those adipocytes lacking collagen VI, isolated 
from collagen VI–/– mice, were unable to sustain tumor growth to 
the same extent. Our studies also demonstrated that early mam-
mary lesions transplanted into cleared mammary fat pads of null 
mice did not progress pathologically. Though these implants had 
functional NG2 receptor, they did not develop into larger primary 
tumors without the collagen VI. These studies further demon-
strate that collagen VI is a critical factor secreted by adipocytes, 
promoting dysplasia and early tumor growth in vivo.
An important issue is how collagen VI manages to exert these 
pro-mitogenic/pro-survival effects on breast cancer cells. Consis-
tent with the role of collagen as a soluble paracrine factor, released 
by adipocytes and acting on adjacent tumor cells, we show by 
immunohistochemistry that murine mammary hyperplasias 
express NG2/CSPG, a previously characterized collagen VI recep-
tor. However, a role for additional receptors for collagen VI, such 
as integrin α2β1, cannot be excluded, particularly in light of the 
fact that our previously published microarray studies that exam-
ined transcriptional changes induced by the total complement of 
secretory proteins in cancer cells showed that integrin α2β1 is sig-
nificantly upregulated upon exposure to adipocyte-conditioned 
medium (4). Nevertheless, the reduction of collagen VI–mediated 
signaling in breast cancer cells (decreased cyclin D1 stabilization) 
using neutralizing antibodies against NG2 suggests that NG2 is a 
major player in the context of mammary tumor growth and col-
lagen VI. The NG2/CSPG receptor has not previously been demon-
strated to promote the phosphorylation of GSK3β or activate the 
downstream Wnt pathway to regulate cyclin D1. In MCF-7 cells, 
we found that collagen VI, deviating from several other ECM pro-
teins, uniquely promotes Tcf/Lef activity and inhibits β-catenin 
degradation. Therefore, collagen VI derived from adipocytes can 
induce a pro-mitogenic signaling cascade downstream of the 
NG2/CSPG receptor, using relatively well-established pathways in 
breast cancer cells to stabilize β-catenin, thereby elevating Tcf/Lef 
activity, which in turn upregulates cyclin D1. The effect of collagen 
VI on breast cancer cells is not limited to MCF-7 cell lines, as our 
in vivo data suggest.
Immunohistochemistry of dysplastic foci and primary tumors 
revealed staining patterns that reflected the in vitro findings. Col-
lagen VI was found in a gradient from adipocytes to breast can-
cer cells. The NG2/CSPG receptor displayed a similar expression 
gradient. Furthermore, relative expressions of pGSK3β and cyclin 
D1 in the presence of collagen VI, compared with the absence of 
collagen VI, resembled those found in MCF-7 cells under similar 
conditions. These results argue that the promotion of dysplasia 
and tumor growth by collagen VI may occur by the same mecha-
nism as illustrated by our in vitro studies. At later stages, the PyMT 
model generates malignant tumors that lead to metastases. Colla-
gen VI did not have an effect on the number of metastases found. 
Collagen VI activity through NG2/CSPG, therefore, is likely to be 
involved in early tumor growth. Subsequently, upon reaching pri-
mary tumor stages and metastatic potential, the tumor cells lose 
their dependence on collagen VI.
Proteomic data derived from PyMT+ColVI+/+, PyMT+ColVI+/–, 
and PyMT+ColVI–/– mice supported our in vitro data. The most 
striking difference was seen in the activation of Akt in malig-
nant cells close to adipocytes expressing collagen VI. There was 
a sharp gradient with respect to the activation state of the pro-
survival factors in the hyperplastic cells adjacent to collagen 
VI–null adipocytes. The increased phosphorylation of Akt sug-
gests that Akt may be the dominant kinase responsible for the 
phosphorylation of GSK3β in vivo.
Detailed proteomic analysis using immunohistochemistry pro-
vides additional insight into the role of collagen VI. The presence of 
collagen VI leads to upregulated cyclin D1 expression. Hyperplas-
tic cells near the periphery of MINs, which are closer to adipocytes, 
express higher levels of cyclin D1 than those closer to the middle of 
MINs. Correspondingly, cells on the periphery of the tumor have 
been found to be more proliferative than those at the core, further 
emphasizing the importance of adipocyte factors including colla-
gen VI in tumor proliferation. Also, in agreement with the in vitro 
signaling data, there was increased staining for pGSK3β on the 
leading edge of tumor cells in the PyMT+ColVI+/+ mice, whereas 
matched tumors from collagen VI–/– mice stained very poorly for 
the pGSK3β molecule. DNA microarray data from MCF-7 cells 
treated with soluble collagen VI additionally demonstrated gene 
induction patterns consistent with the activation of a number of 
genes associated with breast cancer growth and progression.
Immunohistochemistry of human mammary carcinoma tis-
sue reveals strong collagen VI staining around the tumor masses, 
focused primarily around the adipocytes and producing a gradient 
similar to that seen in murine sections. Normal human mammary 
tissue exhibits low-level collagen VI staining. These results dem-
onstrate collagen VI protein presence in human breast tumors. 
While these results do not define collagen VI as a critical factor in 
the development and proliferation of human tumors, the strong 
upregulation of collagen VI expression in human malignant 
lesions combined with the highly provocative mouse data suggests 
that collagen VI may be relevant to human breast cancer as well.
Several independent lines of evidence point toward the potential 
importance of the collagen VIα3 carboxyterminal domains in mod-
ulating the protein’s activity. Published observations described 
that a proteolytic cleavage event that releases this fragment can 
indeed occur upon secretion of the holo-collagen VI complex (40). 
The resulting cleavage product is soluble and may be the fragment 
that has a high affinity for the surrounding breast cancer cells. 
Consistent with such a conclusion is the observation that only 
antibodies to this carboxyterminal domain display a highly signifi-
cant increase in staining intensity in immunohistochemical slides 
during tumor progression. Antibodies recognizing other domains 
on collagen VI display the expected staining pattern primarily 
surrounding adipocytes with little signal detected on the tumor 
cells directly. It is probable that, like other collagens, type VI may 
be cleaved either at the adipocyte cell surface or by the influx of 
proteases in and around tumor cells in the local mammary envi-
ronments during early pathological changes.
The degree of accumulation of the carboxyterminal fragment 
during tumor progression represents systemically a specific event, 
since radiolabeled antibodies against this domain rapidly con-
centrate on the surface of tumor cells with very little additional 
systemic accumulation as judged by our in vivo imaging of tumor-
bearing mice with a radiolabeled antibody. This highlights the 
potential of the collagen VIα3 C-terminus to serve as a sensitive 
in vivo marker that may have significant diagnostic potential. It 
is apparent from our proteomic array studies on human breast 
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tumor extracts that the carboxyterminal domain and the full-
length collagen VI protein are detected at different relative levels, 
depending on whether normal or transformed human breast tis-
sue is examined. The increased C-terminal fragment/full-length 
collagen VI ratio may therefore be a potent prognostic indicator. 
Future studies on a much larger number of specimens will have to 
address the general usefulness of this ratio with respect to predic-
tion of future disease outcome and whether neutralization of the 
carboxyterminal domain of collagen VIα3 fragment through the 
use of specific antibodies may serve as a therapeutic modality for 
early-stage breast cancer therapy in humans.
In summary, we propose a model that involves adipocyte-derived 
collagen VI, particularly a carboxyterminal fragment of collagen 
VIα3 that is either produced at higher levels or has an increased 
half-life during tumor progression, presumably as a result of the 
local paracrine interactions between the tumor cells and the sur-
rounding adipocytes. This fragment accumulates on tumor cells, 
where, through activation of the NG2 receptor, it triggers the acti-
vation of specific signaling pathways that involve β-catenin, lead-
ing to a further pro-mitogenic response for the cancer cells.
Methods
Proteins and reagents. DMEM was prepared at the Albert Einstein Cancer 
Center media preparation facility. Human type VI collagen (99.9% homoge-
neity) was obtained from Research Diagnostics Inc. Human collagen I was 
obtained from Collaborative Biomedical Products. Collagen I and collagen 
VI were used at a concentration of 30 μg/ml unless otherwise stated. The 
mAb to β-catenin was obtained from Transduction Laboratories. A rabbit 
polyclonal anti–collagen VI antibody specific to the C-terminal of the α3 
subunit was generated using a bacterially produced GST-fusion protein 
raised against the last 70 amino acids of mouse collagen VIα3. A monoclo-
nal anti–collagen VI antibody was obtained from Chemicon International 
Inc. The antibody against NG2 was a kind gift from Joel M. Levine (State 
University of New York at Stony Brook, Stony Brook, New York, USA). The 
anti–GDI-3 antibody was a gift from Perry Bickel (Washington University, 
St. Louis, Missouri, USA).
Laboratory animals. Mice were housed in groups of 2–5 in filter-top cages and 
given free access to water and standard laboratory chow diet. The colonies 
were maintained in a pathogen-free Association for Assessment and Accredi-
tation of Laboratory Animal Care–accredited facility at the Albert Einstein 
College of Medicine under controlled environment settings (22–25°C, 40–
50% humidity, 12-hour/12-hour light/dark cycle). All mouse strains (MMTV-
PyMT, collagen VI–null mutant, and aP2-DTA) were maintained in a pure 
FVB background. All animal protocols were approved by the Albert Einstein 
Animal Committee of the Albert Einstein College of Medicine.
Cell culture. 3T3-L1 cells were propagated and differentiated as previ-
ously described (41). NIH-3T3 cells were grown and propagated in DMEM 
containing 10% donor calf serum and antibiotics. SUM-159PT cells were 
grown in 5% charcoal-stripped FCS, 10% Ham’s F12 nutrient medium, 
sodium bicarbonate, 10 mM HEPES, and 25 mM glucose (26). The SUM-
159PT medium was adjusted to pH 7.1. Met1 and dB7 cells were a generous 
gift of Robert Cardiff (University of California, Davis, California, USA) and 
were grown in 10% FCS-DMEM. MCF-7 cells were used for in vitro signal-
ing experimentation and were grown in 10% FCS-DMEM as well.
In vivo tumorigenesis assay. The reconstituted in vivo tumor model used 
3T3-L1 adipocytes or primary adipocytes (obtained by collagenase treat-
ment of adipose tissue followed by centrifugation and removal of stromal 
cells) in combination with fluorescently tagged SUM-159PT cells. Mice 
received injections of 3 × 105 adipocytes and 1 × 104 SUM-159PT cells. Cells 
were implanted by s.c. injection in the flank of male 6- to 8-week-old, nude 
mice obtained from The Jackson Laboratory. Mice were killed 4 weeks after 
injection. After excision, tumor size (area and wet weight) was recorded.
Immunoblotting. Separation of proteins by SDS-PAGE fluorography and 
immunoblotting were performed as previously described (42). For Western 
blots used to examine phosphorylated protein products, TNET lysis buffer 
(1% Triton X-100, 150 mM NaCl, 5 mM EDTA pH 8.0, 50 mM Tris pH 8.0) 
was supplemented with 50 mM NaF, 30 mM sodium pyrophosphate, and 
100 μM sodium orthovanadate.
Luciferase assays. MCF-7 or SUM-159PT cells were seeded in 12-well plates 
sufficient to reach 50–60% confluence the next day. Two days before the 
luciferase readout, cells were transiently transfected with the TOPFLASH 
luciferase promoter construct (which contains 4 Tcf/Lef–binding elements) as 
well as a thymidine kinase–driven renilla luciferase construct as a transfection 
control vector (Promega Corp.) (39). SuperFect transfection reagent (QIAGEN 
Corp.) was used, and, for 12-well plates, 1.5 μg of DNA per well. Approxi-
mately 30 hours after the transfection, collagen I or VI at the indicated levels 
was added to the cells for 3 hours. Subsequently, cells were processed using a 
dual-luciferase assay system for luciferase activity from both the TOPFLASH 
constructs and the renilla constructs. All results were standardized to the rela-
tive transfection efficiencies as observed from the renilla values.
Metabolic labeling for β-catenin. MCF-7 cells, seeded in 6-well plates, were 
treated in methionine/cysteine–deficient DMEM for 1 hour. Samples 
were pulsed with 500 μCi/ml [35S]-methionine/cysteine for 20 minutes 
and chased in the presence of cycloheximide supplemented with either 
vehicle or 30 μg/ml collagen I or VI for various time periods. After pulsing, 
the cells were washed with DMEM twice and lysed in a TNET buffer (con-
taining 1 μM phenylmethanesulfonyl fluoride and 60 mM octylgluco-
side). The lysates were cleared with Sepharose 4CL beads and subjected to 
β-catenin immunoprecipitation and anti–GDI-3 immunoprecipitation. 
The immunoprecipitates were subjected to electrophoresis on an SDS-
PAGE gel and treated in 1 M sodium salicylate for 30 minutes. Subse-
quently, the gel was dried and exposed to film. We have previously shown 
that GDI-3 has an extended half-life and that its signal remains stable for 
at least 2 hours (29).
Microarray analysis. MCF-7 cells at 60% confluence were treated with 
type VI or type I collagen for 7 hours. Total RNA was isolated by treatment 
with TRIzol. Human microarrays (9,596 spots) from the Albert Einstein 
College of Medicine were obtained and used for experimentation. Reverse 
transcription with the concomitant incorporation of Cy3- and Cy5-labeled 
nucleotides was performed on 100 μg of total RNA. The reverse-transcribed 
RNA was incubated on the microarrays and subsequently analyzed using 
Scanalyze software (Digital Michelangelo Project, Stanford University) 
according to the standardized protocol of the Albert Einstein College of 
Medicine (as described in ref. 4). Each independent experiment incorpo-
rated data from 3 separate chips and 3 separate RNA isolations as well as a 
reversal of the incorporated labeled nucleotides.
Tissue recovery for protein microarray. Whole mammary tissue samples were 
recovered from MMTV-PyMT+ mice that were in either a collagen VI WT 
or a collagen VI knockout background. Mammary glands were removed 
and placed in cryomolds, covered with OCT compound, and immediately 
frozen in isopentane and stored at –80°C.
Sectioning and staining. The OCT-embedded tissue blocks were cut with a 
Tissue-Tek 2000 cryostat (Sakura Products) into 8-μm sections and placed 
onto plain, uncharged microscope slides. The frozen tissue section slides 
were stored at –80°C until microdissection. Only 1 section was thawed and 
dissected at a time to minimize degradation of proteins. Frozen sections 
were submerged sequentially in 70% ethanol, deionized water, hematoxy-
lin (DakoCytomation), Scott’s tap water (bluing solution; Fisher Scientific 
International Co.), and 70%, 95%, and 100% ethanol for 10 seconds each 
with final dehydration for 10–30 seconds in Sub-X (xylene-substitute clear-
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ing agent; Surgipath Medical Industries Inc.). Protease inhibitors (Roche 
Diagnostics Corp.) were added to both the 70% ethanol and the water solu-
tions. The tissue section was air-dried before microdissection.
Murine immunohistochemistry. Mammary tumor tissues were excised from 
MMTV-PyMT transgenic mice euthanized with CO2, and the tissues were 
fixed in 10% neutral-buffered formalin at room temperature overnight. The 
tissue was embedded in paraffin, and 6- to 8-μm sections were made. The 
sections represented breast tumors from various stages of development, 
from adenomas to late-stage carcinomas. An avidin-biotin-peroxidase 
staining system was used along with 3,3′-diaminobenzidine tetrahydro-
chloride as the chromogen. Sections were blocked to prevent nonspecific 
binding with 10% horse serum, and the polyclonal collagen VI antibody 
was added to the sections and incubated in a humidified chamber at 4°C 
overnight. Sections were washed twice in PBS between each incubation. 
Endogenous peroxidase was quenched with 3% H2O2 in methanol for 30 
minutes at room temperature. A biotin-labeled anti-rabbit secondary anti-
body was applied for 30 minutes at room temperature, followed by incuba-
tion with a preformed avidin-biotinylated enzyme complex for 30 minutes. 
Chromogen was subsequently added, the cells were counterstained with 
H&E when necessary to improve contrast of the images, and the slides were 
finally mounted and examined by light microscopy. Polyclonal antibody 
to Ki67 was obtained from Santa Cruz Biotechnology Inc., pAkt mAb to 
serine residue 473 from Cell Signaling Technology Inc., and pGSK3b anti-
body to serine residue 9 from Cell Signaling Technology Inc., and collagen 
VI antibodies were generated in the laboratory.
Magnetic resonance imaging. All images were obtained using a 9.4-tesla hor-
izontal imaging system. Mice were anesthetized with isoflurane (1.5% in 
oxygen) delivered via a nose cone and were positioned in a 25-mm birdcage 
1H coil. Body temperature was maintained with a homeothermic system. 
To quantitatively assess whole-body fat and water, each mouse was sub-
jected to a 16-scan pulse-acquire sequence, and spectra, including the water 
and fat peaks, were obtained and integrated. For imaging, several data sets 
of 9 slices of 1-mm thickness spanning the whole body (the gap between 
slices was 1 mm) were obtained. Imaging was conducted using a routine 
spin-echo pulse sequence (18-millisecond echo time, 600-millisecond rep-
etition time, and averages of 2 signals per scan).
In vivo imaging of the carboxyterminal domain of collagen VIα3. Preimmune and 
collagen-specific polyclonal antibodies were radiolabeled directly with 188-
rhenium (188Re) via reduction of antibody disulfide bonds with dithiothreitol 
(43). An amount of 2–4 mCi 188ReO4– in saline was reduced by incubation 
with 20 mg sodium gluconate and 20 μl 20 mg/ml SnC12 in 0.1 M HC1 at 
37°C for 60 minutes. Reduced 188Re(V)-gluconate was combined with reduced 
and purified antibodies and kept at 37°C for 60 minutes. Radioactivity not 
bound to the antibody was removed by centrifugal purification on Centricon-
30 microconcentrators (Millipore Corp.). Tumor-bearing mice were injected 
i.p. or i.v. with 0.5 mCi 188Re-Ab (100 μg). At 1.5 hours after injection, the 
animals were anesthetized with isoflurane and scintigraphically imaged on a 
LEM+ZLC DIGITRAC gamma camera (Siemens AG) equipped with a pinhole 
collimator and ICON image-processing software (ICON Corp.).
Whole-mount analysis. The fourth and fifth mammary glands of female 
mice were excised. The glands were maintained in a 75% acetic acid/meth-
anol fixative for 4 hours. Subsequently, the sections were rehydrated in 
increasing ratios of water to ethanol for 20 minutes and put in carmine red 
solution overnight. The samples were then treated with xylene, and photo-
graphs were taken. The area of early hyperplasia per gland was determined 
using NIH ImageJ software.
Patients and surgically resected frozen tissues. The study set consisted of 17 pri-
mary human breast cancer samples and 7 healthy control samples taken from 
patients undergoing breast reduction surgery. Both human and animal stud-
ies were approved by the Institutional Review Boards of the National Cancer 
Institute and Lombardi Comprehensive Cancer Center, Georgetown Uni-
versity. All carcinomas were infiltrating ductal carcinomas. Frozen sections 
were prepared for laser-capture microdissection on plain glass microscope 
slides. Microdissection was performed with a PixCell II system (Arcturus 
Engineering Inc.). Microdissected areas represented tumor from the breast 
cancer cases or normal-appearing mammary ducts adjacent to the tumor 
from the same patient, or mammary ductal epithelium from the unaffected 
patients undergoing reduction mammoplasty. Protein was extracted from 
the microdissected cells using 10 μl of extraction buffer per 1,000 micro-
dissected cells (1:1 dilution of 4% β-mercaptoethanol in 2× Tris-glycine-
SDS buffer [Invitrogen Corp.] with liquid tissue protein extraction reagent 
[T-PER; Pierce Chemical Co.]) for 1 hour at 70°C. After protein extraction, 
samples were boiled for 5 minutes, and serial dilutions representing 1:1, 
1:3, and 1:9 concentrations and a negative control were prepared in extrac-
tion buffer. Three nanoliters of the sample and control lysates were arrayed 
onto glass-backed nitrocellulose slides (FAST slides; Schleicher & Schuell 
BioScience) using a GMS 417 pin-and-ring-style arrayer (Affymetrix Inc.). 
Arrays were treated with mild ReBlot solution (Chemicon International Inc.) 
for 15 minutes, washed twice for 5 minutes each in 1× PBS without calcium 
or magnesium, and blocked for a minimum of 30 minutes at room tempera-
ture with I-Block protein block solution (Applied Biosystems). Arrays were 
probed with antibodies to total and cleaved collagen VI using an automated 
slide stainer (DakoCytomation) with a catalyzed signal amplification system 
(DakoCytomation). A rabbit polyclonal anti–collagen VI antibody specific to 
the C-terminal of the α3 subunit was generated using a bacterially produced 
GST-fusion protein raised against the last 70 amino acids of mouse collagen 
VIα3. A monoclonal anti–collagen VI antibody was obtained from Chemicon 
International Inc. Polyclonal primary antibody was used at a final dilution of 
1:1,000. Monoclonal primary antibody was used at a final dilution of 1:250. 
One slide was stained for total protein with SYPRO Ruby Protein Blot stain 
(Invitrogen Corp.) according to the manufacturer’s instructions. The slide 
was imaged with an Alpha Innotech Corp. imager equipped with a SYPRO 
Red/Texas red filter. Exposure time was 20 seconds. Quantification of the 
relative pixel density of each array spot was performed with ImageQuant 
software version 5.2 (Molecular Dynamics).
Arrays were allowed to air dry, and images were scanned on an Epson 
1640SU flatbed scanner (Epson Corp.). Quantitation of the relative pixel 
density of each array spot was performed with ImageQuant software ver-
sion 5.2 (Molecular Dynamics). Each intensity value was normalized to its 
total protein relative intensity value. The ratio of the spot intensity of the 
cleaved carboxyterminal domain of collagen VIα3 to that of the full-length 
collagen VI transcript was calculated.
Laser-capture microdissection and protein extraction for mouse samples. Microdis-
section was carried out using a PixCell II and AutoPix Laser Capture Micro-
dissection System (Arcturus Engineering Inc.). Four areas were microdis-
sected from the WT-phenotype frozen tissue sections, representing 34,000 
cells. Ten areas were microdissected from the knockout-phenotype tissue 
sections, representing 26,830 cells. Within each tissue section, only mam-
mary tumor cells were microdissected. The microdissected samples were 
frozen at –80°C until molecular analysis. Protein was extracted from the 
microdissected cells using 10 μl of extraction buffer per 1,000 microdis-
sected cells (1:1 dilution of 4% β-mercaptoethanol in 2× Tris-glycine-SDS 
buffer [Invitrogen Corp.] with liquid tissue protein extraction reagent 
[T-PER; Pierce Chemical Co.]) for 1 hour at 70°C.
Total protein blot assay. One slide was stained for total protein with SYPRO 
Ruby Protein Blot stain (Invitrogen Corp.) according to the manufacturer’s 
instructions. The slide was imaged with an Alpha Innotech Corp. imager 
equipped with a SYPRO Red/Texas red filter. Exposure time was 20 sec-
onds. Quantification of the relative pixel density of each array spot was 
performed with ImageQuant software version 5.2 (Molecular Dynamics). 
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Experiments were performed at the Laser Capture Microdissection Core 
facility of the National Cancer Institute.
Protein biotinylation and microarray. After protein extraction, samples were 
boiled for 5 minutes, and serial dilutions representing 1:1, 1:2, 1:4, 1:8, and 
1:16 concentrations and a negative control were prepared in extraction buf-
fer. A control lysate of Jurkat cells treated with activating anti-Fas (Upstate 
Biotechnology) was prepared in a similar manner. Three nanoliters of the 
sample and control lysates were arrayed onto glass-backed nitrocellulose 
slides (FAST slides; Schleicher & Schuell BioScience) using a GMS 417 pin-
and-ring-style arrayer (Affymetrix Inc.). Arrays were treated with mild ReBlot 
solution (Chemicon International Inc.) for 15 minutes, washed twice for 5 
minutes each in 1× PBS without calcium or magnesium, and blocked for 30 
minutes at room temperature with I-Block protein block solution (Applied 
Biosystems). Arrays were probed with antibodies to total and phosphorylated 
proteins using an automated slide stainer (DakoCytomation) with a cata-
lyzed signal amplification system (DakoCytomation). Polyclonal primary 
antibodies were used at the following final dilutions: 1:250 anti-Akt (Cell 
Signaling Technology Inc.), 1:250 anti-pAkt (ser472/473/474; BD), 1:50 anti-
EGFR (Cell Signaling Technology Inc.), 1:100 anti-pEGFR (Y1068; Cell Sig-
naling Technology Inc.), 1:200 anti-GSK3β (BD), 1:200 anti-pGSK3β (ser9; 
Cell Signaling Technology Inc.), 1:100 anti-ErbB2 (Cell Signaling Technol-
ogy Inc.), 1:1,000 anti-pErbB2 (Y1248; Cell Signaling Technology Inc.), 1:500 
anti-pSTAT1 (Y701; Cell Signaling Technology Inc.), and 1:100 anti–NF-κB 
(Cell Signaling Technology Inc.). Biotinylated secondary antibody solution 
was used at the final concentration of 1:5,000 goat anti-rabbit IgG H+L 
(Vector Laboratories Inc.). Chromogenic detection was with 3,3′-diamino-
benzidine tetrahydrochloride solution (DakoCytomation).
Image analysis. Arrays were allowed to air dry, and images were scanned 
on an Epson 1640SU flatbed scanner. Quantitation of the relative pixel 
density of each array spot was performed with ImageQuant software ver-
sion 5.2 (Molecular Dynamics). Each intensity value was normalized to its 
total protein relative intensity value.
Tumor transplant experiments. Polyoma middle T transgenic mice with 
mammary tumors were sacrificed, and large, late tumor sections (from 
lesions larger than 1,500 mm3) and some small transformed mammary 
tissue from early tumor samples (lesions smaller than 300 mm3) were iso-
lated. These tissues were kept in PBS on ice while all the mice (4 collagen 
VI+/+ and 4 collagen VI–/–) were being dissected. Each mouse was anesthe-
tized with ketamine/xylazine and received an inverted “Y” incision along 
the midline and between the fourth and fifth nipples. One side at a time 
was completed by pinning the skin back and then making a small pocket 
with iris forceps for placement of the tumor tissue. In each partially cleared 
mammary fat pad, an approximately 15- to 20-mg dissected piece from 
the tumor tissue was transplanted (each piece was in the shape of a small 
cube with 3-mm dimensions). Finally, the mice were closed with wound 
clips. After 3 weeks, the mice were dissected open, and the entire mammary 
gland with transplanted tissue was fixed in Carnoy’s fixative (6 parts 100% 
ethanol, 3 parts CHCl3, 1 part glacial acetic acid) for 2 hours, rehydrated 
to 100% water in 20 minutes, and placed in carmine stain overnight. The 
next day, the whole-mount preparations were dehydrated with increasing 
concentrations of ethanol and placed in xylene to remove the fat. Pictures 
were taken and lesion sizes compared with NIH Image software. Sections 
were also saved in formalin for H&E staining.
Production and use of recombinant collagen VIα3 carboxyterminal fragment pro-
tein in signaling. In order to test the functional role of the carboxyterminal 
cleavage product of collagen VIα3, recombinant protein was produced in 
HEK-293T cells through transient transfections. The signal sequence of 
human adiponectin followed by a short decapeptide (the hypervariable 
region of adiponectin, which is used as an antibody tag in this case) was 
fused to the carboxyterminal C3–C5 domains of collagen VIα3 at the 
cDNA level. This open reading frame was then inserted into pRA-GFP (44) 
and transiently transfected into HEK-293T cells. Protein expression was 
verified with immunoprecipitation–pulse-chase analysis and Western blot-
ting using antibodies against the carboxyterminal fragment of collagen 
VIα3 domain and antibodies against the human adiponectin hypervariable 
region. Empty vector plasmid (pRA-GFP) was used as control in the experi-
ments in parallel. Forty-eight hours after transfection, fresh serum-free 
medium (DMEM containing 1% BSA) was added to the cells, which were 
then allowed to secrete protein for an additional 24 hours. The conditioned 
media were collected from either collagen VI fragment–expressing cells or 
control cells, and transferred to MCF-7 cells, which had been seeded in 24-
well plates at a density of 5 × 104 per well 1 day before. After every 24 hours 
of treatment, media were removed from the MCF-7 cells and replaced with 
conditioned medium freshly harvested from HEK-293T cells. At the indi-
cated time periods, MCF-7 cells were washed with PBS and trypsinized, 
and the cells from each well were counted. The experiments were done in 
triplicate, and the results presented as mean ± SD.
Reverse transcription and quantitative real-time PCR. TRIzol reagent 
(Invitrogen Corp.) was used to isolate total RNA from murine tissue sam-
ples according to the manufacturer’s protocol. Mammary adipose tissue 
and sections from early- and late-stage tumors were isolated and snap-fro-
zen before RNA isolation. Early tumors were characterized as being 300 
mm3 or smaller, whereas late-stage tumors were 1,500 mm3 or larger. Mul-
tiple sections were taken from multiple tumors. Care was taken to ensure 
that no adipose tissue was removed at the time of tumor-tissue excision. 
Mammary adipose tissue was removed and the adipocytes isolated as previ-
ously described using collagenase I. cDNAs were synthesized from 1 μg of 
total RNA using random hexamers and the MultiScribe reverse transcrip-
tion kit (Applied Biosystems) as instructed by the manufacturer.
PCR reactions containing 10 ng of cDNA, SYBR Green sequence detec-
tion reagents (Applied Biosystems), and gene-specific primers were assayed 
on an ABI 7700 sequence detection system (Applied Biosystems). Primers 
designed for murine collagen VI are as follows: forward 5′-TCAAACTGT-
TAACTCAGGAC-3′ and reverse 5′-ACAGAACCATTGTTTCTCAC-3′. 
These primers amplify a unique, approximately 200-bp fragment of the 
collagen VIα3 domain. The accumulation of PCR products was measured 
in real time as the increase in SYBR Green fluorescence. Data were analyzed 
using the Sequence Detector program version 1.9.1 (Applied Biosystems). 
All reactions were performed in triplicate. The accumulation of GAPDH 
was used as an internal control. Before the running of the actual samples, 
a determination was made to verify the concentration that would lead to 
optimal DNA amplification. All results were standardized to the level of 
GAPDH produced in the various reactions.
For the PCR analysis of cultured cells, the 1-step RT-PCR kit from 
QIAGEN Inc. was used. Initially, the MCF-7 cells and human adipocytes 
were processed for total RNA isolation using the TRIzol reagent system. 
Subsequently, the isolated RNA was processed using the above kit with the 
appropriate primers to generate both cDNA and amplification of the DNA 
in a semiquantitative method.
Statistical analysis. All statistical analysis was performed with numerical 
data represented throughout the figures as mean ± SEM. P values equal 
to or less than 0.05, as calculated by Student’s t test, were considered 
statistically significant.
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